Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Bruce Sullenger
Duke University, Department: Surgery
Should you be removed from our database? Contact us at [email protected]. Read more below.
Tobira Therapeutics
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
Dr. Sullenger uses his licensed IP as a tool in this research. This was formerlly reported under 5R01-HL65222 and Regado Biosciences was the company in which the IP was licensed to. Regado was merged with Tobira Therapeutics.
Antithrombotic Aptamers and Antidotes
The long-term objective of this project is and has been to create safe and effective, rapid onset anticoagulants (ROAs) to improve clinical outcomes for the millions of Americans requiring such therapeutics each year. With the support of this award, we have made significant progress toward addressing this important medical need. Our factor IXa aptamer and its antidote, made possible by this award, is currently being evaluated in a phase 3 clinical trial in 13,200 acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) and was recently awarded Fast Track Development status by the United States Food and Drug Administration (FDA) as this novel ROA strategy was deemed by the FDA to address an unmet medical need for treating patients undergoing PCI. Nevertheless, our recent studies indicate that aptamer-mediated factor IXa inhibition alone will not be sufficient for other indications requiring ROA. Therefore, herein we propose studies focused upon developing a more thorough mechanistic understanding of anticoagulant aptamers and their inhibitory effects to serve as the basis for developing aptamer-based ROA for other indications.
Filed on August 31, 2015.
Tell us what you know about Bruce Sullenger's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Bruce Sullenger filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Bruce Sullenger | Duke University | Conflict of Interest | Tobira Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.